Wed. 8 May 2024, 5:37pm ET
Benzinga
Earnings, Earnings Misses, News
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.23) by 12.2 percent. This is a 9.8 percent increase over losses of $(1.53) per share from the same period last year. The company reported quarterly sales of $15.622 million which missed the analyst consensus estimate of $23.525 million by 33.59 percent. This is a 18.37 percent decrease over sales of $19.138 million the same period last year.